For HER2+ metastatic
breast cancer (mBC)
Actor portrayals.
HER2+=human epidermal growth factor receptor 2 positive.
For HER2+ metastatic breast cancer (mBC)
Actor portrayals.
HER2+=human epidermal growth factor receptor 2 positive.
MARGENZA is a prescription medicine approved for use in combination with chemotherapy for the treatment of adult patients with metastatic HER2‑positive breast cancer who have received two or more prior anti‑HER2 regimens, at least one of which was for metastatic disease.
Find co-pay and financial assistance information for eligible patients.
TerSera SupportSource for MARGENZA is available Monday–Friday 9 AM to 6 PM ET
MAR-P-0374 (03/2026)
Infusion-related reactions. MARGENZA is a medicine that is delivered into a vein through a needle as an infusion. MARGENZA has been associated with infusion-related reactions which can include fever, chills, joint pain, cough, dizziness, tiredness, nausea, vomiting, headache, sweating, fast heart rate, low blood pressure, itching, rash, hives, and shortness of breath. Your healthcare team will monitor you during treatment with MARGENZA and may slow or stop your infusion if you have side effects. You may need to permanently stop MARGENZA if you have a severe infusion reaction.
Before you receive MARGENZA, tell your doctor if you are breastfeeding. It is not known if MARGENZA could pass into breast milk and harm your baby.
The most common side effects with MARGENZA in combination with chemotherapy are:
These are not all the possible side effects of MARGENZA. Your doctor may stop treatment if serious side effects happen. Be sure to contact your healthcare team right away if you have questions or are worried about any side effects.
You are encouraged to report negative side effects of prescription drugs to the FDA. To report SUSPECTED ADVERSE REACTIONS, contact the FDA at
Please see accompanying Full Prescribing Information, including BOXED WARNING.
MARGENZA is a prescription medicine approved for use in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
Please see accompanying Full Prescribing Information, including BOXED WARNING.
Infusion-related reactions. MARGENZA is a medicine that is delivered into a vein through a needle as an infusion. MARGENZA has been associated with infusion-related reactions which can include fever, chills, joint pain, cough, dizziness, tiredness, nausea, vomiting, headache, sweating, fast heart rate, low blood pressure, itching, rash, hives, and shortness of breath. Your healthcare team will monitor you during treatment with MARGENZA and may slow or stop your infusion if you have side effects. You may need to permanently stop MARGENZA if you have a severe infusion reaction.
Before you receive MARGENZA, tell your doctor if you are breastfeeding. It is not known if MARGENZA could pass into breast milk and harm your baby.
The most common side effects with MARGENZA in combination with chemotherapy are:
These are not all the possible side effects of MARGENZA. Your doctor may stop treatment if serious side effects happen. Be sure to contact your healthcare team right away if you have questions or are worried about any side effects.
You are encouraged to report negative side effects of prescription drugs to the FDA. To report SUSPECTED ADVERSE REACTIONS, contact the FDA at
Please see accompanying Full Prescribing Information, including BOXED WARNING.
MARGENZA is a prescription medicine approved for use in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
Please see accompanying Full Prescribing Information, including BOXED WARNING.
The information contained in this section of the site is intended for US Healthcare Professionals only. Click Continue if you are a healthcare professional.
If you click “Continue” below, you will leave the current site.
TerSera is not responsible for the privacy policy of any